Pasithea Therapeutics Warrants
KTTAW
3 hedge funds and large institutions have $49.6K invested in Pasithea Therapeutics Warrants in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.09% less ownership
Funds ownership: 6.21% → 6.12% (-0.09%)
40% less funds holding
Funds holding: 5 → 3 (-2)
79% less capital invested
Capital invested by funds: $240K → $49.6K (-$190K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $30K | – | – | – |
|
|
KC
2
Kepos Capital
New York
| $10K | – | – | – |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $9.55K | -$1.22K | -20,915 | -7% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2K | -10,653 | Closed |
|
KTTAW Hedge Fund Activity: Q4 2022 in Review
3 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q4 2022, worth a combined $49.6K — down 79% from $240K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KTTAW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $2K sold.
- 3 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q4 2022, down from 5 in Q3 2022.
- Funds reported $49.6K of Pasithea Therapeutics Warrants stock for Q4 2022, down 79% quarter-over-quarter.
- 0 funds opened new Pasithea Therapeutics Warrants positions in Q4 2022 and 2 closed out, a net change of -2 holders.
- The largest Pasithea Therapeutics Warrants seller in Q4 2022 was Susquehanna International Group, an estimated $2K sold.
Based on aggregated 13F filings for Q4 2022.